0001140361-16-070358.txt : 20160620
0001140361-16-070358.hdr.sgml : 20160620
20160620202313
ACCESSION NUMBER: 0001140361-16-070358
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160616
FILED AS OF DATE: 20160620
DATE AS OF CHANGE: 20160620
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 161723188
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
4
1
doc1.xml
FORM 4
X0306
4
2016-06-16
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001221590
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL
CA
94901
1
1
0
0
Chief Executive Officer
Common Stock
2016-06-16
2016-06-16
4
M
0
41666
17.54
A
420250
D
Common Stock
2016-06-16
2016-06-16
4
S
0
41666
80.55
D
378584
D
Common Stock
25758
I
Shares held by Bienaime Family Trust
Stock Option (right to buy Common Stock)
17.54
2016-06-16
2016-06-16
4
M
0
41666
0
D
2007-05-20
2016-11-19
Common Stock
41666
208334
D
Trade made pursuant to a 10b5-1 plan executed on August 17, 2015. Mr. Bienaime's former spouse will receive approximately 17% of the net proceeds from the sale of these shares pursuant to a marital separation agreement between Mr. Bienaime and his former spouse.
The price in column 4 is the weighted average price. The price actually received ranged from $78.39 to $83.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Reflects the number of stock options outstanding after the transaction from this specific stock option grant.
/s/ Laura Randall Woodhead, Attorney-in-Fact
2016-06-20